Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 17, 2020 (Event Date)
Reporting Period: The filing covers a specific corporate event: the entry into an underwriting agreement on June 17, 2020, and the subsequent closing of the offering on June 22, 2020.
Key Financial Metrics
This filing details a capital raise event rather than periodic operating results. Key financial figures related to the transaction include:
- Shares Issued: 6,666,667 shares of Common Stock.
- Public Offering Price: $15.00 per share.
- Price to Underwriters: $14.10 per share.
- Net Proceeds: Approximately $93.5 million (after deducting underwriters' discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,000,000 additional shares at the public offering price.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels as this is a transaction report, not a financial statement.
Material Changes
The primary material change is the increase in the company's cash liquidity through the completion of the public offering. The company transitioned from agreeing to the terms on June 17, 2020, to closing the transaction and receiving net proceeds on June 22, 2020.
Guidance, Outlook, and Risks
- Lock-Up Agreements: The Company, its directors, and executive officers agreed not to sell or transfer Common Stock for 90 days following the date of the Prospectus. One affiliated holder agreed to a 60-day lock-up period.
- Indemnification: The Company agreed to indemnify the underwriters against certain liabilities under the Securities Act of 1933.
- Management Commentary: The filing does not contain forward-looking guidance or management commentary regarding future operations beyond the details of the offering.
Investor Verification Checklist
- Verify the final closing date of the offering (June 22, 2020) and confirm the exact net proceeds received.
- Check if the underwriters exercised the option to purchase the additional 1,000,000 shares within the 30-day window.
- Review the prospectus supplement for the specific use of proceeds and detailed offering expenses.
- Confirm the status of the 90-day lock-up period for directors and officers.